1. Ha YC, Kim TY, Lee A, et al. Current trends and future projections of hip fracture in South Korea using nationwide claims data. Osteoporos Int. 2016; 27:2603–2609.
Article
2. Lee SR, Ha YC, Kang H, et al. Morbidity and mortality in Jeju residents over 50-years of age with hip fracture with mean 6-year follow-up: a prospective cohort study. J Korean Med Sci. 2013; 28:1089–1094.
Article
3. Madureira MM, Ciconelli RM, Pereira RM. Quality of life measurements in patients with osteoporosis and fractures. Clinics (Sao Paulo). 2012; 67:1315–1320.
Article
4. Abimanyi-Ochom J, Watts JJ, Borgström F, et al. Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS). Osteoporos Int. 2015; 26:1781–1790.
Article
5. Park C, Ha YC, Jang S, et al. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab. 2011; 29:744–751.
Article
6. Peng J, Liu Y, Chen L, et al. Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: a meta-analysis. Pak J Med Sci. 2016; 32:499–504.
Article
7. Center JR, Bliuc D, Nguyen ND, et al. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011; 96:1006–1014.
Article
8. Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int. 2003; 14:722–727.
Article
9. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD001155.
Article
10. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD004523.
Article
11. Zhou J, Ma X, Wang T, et al. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 2016; 27:3289–3300.
Article
12. Rhee Y, Kang M, Min Y, et al. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Osteoporos Int. 2006; 17:1801–1807.
Article
13. Watts NB, Worley K, Solis A, et al. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm. 2004; 10:142–151.
Article
14. Foster SA, Shi N, Curkendall S, et al. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health. 2013; 13:15.
Article
15. Modi A, Tang J, Sen S, et al. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment. Curr Med Res Opin. 2015; 31:767–777.
Article
16. Iwamoto J, Takeda T, Sato Y, et al. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis. J Bone Miner Metab. 2005; 23:238–242.
Article
17. Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006; 91:2631–2637.
Article
18. Tan W, Sun J, Zhou L, et al. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis. J Clin Pharm Ther. 2016; 41:519–523.
Article
19. Suh HW, Kim HO, Kim YS, et al. The efficacy and safety of a combined alendronate and calcitriol agent (Maxmarvil): a postmarketing surveillance study in Korean postmenopausal women with osteoporosis. Korean J Fam Med. 2012; 33:346–355.
Article